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A B S T R A C T
Background: Studies have shown that omega-3 (n-3) Polyunsaturated Fatty Acids (PUFAs), including doc-
osahexaenoic acid (DHA), might have beneficial effects on somatic and mental health, potentially partly due to
their mitigating effects on three major biological stress systems: the immune-inflammatory system, the hy-
pothalamic-pituitary-adrenal-axis (HPA-axis) and the autonomic nervous system (ANS).
Objective: To examine the association between (cumulative measures of) markers of three biological stress
systems and n-3 PUFA and DHA plasma levels.
Design: Plasma n-3 PUFA and DHA were measured using Nuclear Magnetic Resonance in 2724 participants from
the Netherlands Study of Depression and Anxiety. Linear regression analyses (adjusted for sociodemographic,
sampling, lifestyle and somatic disease variables) associated inflammation (C-reactive protein, interleukin-6,
tumor necrosis factor alpha), HPA-axis (cortisol awakening response and evening cortisol) and ANS (heart rate,
respiratory sinus arrhythmia and pre-ejection period) markers and cumulative indices within and across stress
systems as independent variables with n-3 PUFA and DHA levels as dependent variables.
Results: Participants had a mean age of 41.8 (SD=13.1) and 65.7% were female. Higher levels of all three
inflammation markers (Beta=−.146 to −.073, all p-values< .001), evening cortisol (Beta=−.045, p= .033)
and heart rate (Beta=−.080, p < 0.001) were significantly negatively associated with n-3 PUFA. Suggesting an
exposure-response relationship, a higher number of markers indicative of inflammation and hyperactive HPA-
axis (p < .001 and p= .003, respectively), but not of ANS dysregulation, was found in persons with lower n-3
PUFA levels. An exposure-response relationship was also found for having a higher number of different stress
system dysregulations with lower n-3 PUFA levels (p < .001). For DHA, results were in line with those for n-3
PUFA, although with slightly smaller effect sizes.
Conclusions: Our study confirmed that having various (cumulative) indicators of dysregulation of three biolo-
gical stress systems was significantly associated with lower n-3 PUFA and DHA plasma levels. If low n-3 PUFA
levels are the cause of dysregulated stress systems, then n-3 PUFA supplementation might reduce biological
stress and thereby improve somatic and mental health.
1. Introduction
Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) consist of e.g. α-
linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), and are primarily found in fatty fish, along with some other
seafood, and certain nuts and seeds (Simopoulos, 1999). N-3 PUFAs
have anti-inflammatory properties and are suggested to positively in-
fluence brain functioning (Smith et al., 2011). Low levels of n-3 PUFAs
are observed in patients with several somatic or mental disorders, and
accordingly several intervention studies have found a beneficial effect
of n-3 PUFA supplementation on, for example, cardiovascular disease,
diabetes mellitus, obesity, inflammatory diseases, and neurological/
neuropsychiatric disorders (Yashodhara et al., 2009), although this is
not consistent in all studies (Kromhout et al., 2010; Rizos and Elisaf,
2017; Zhang et al., 2016).
It has been suggested that part of the beneficial effect of n-3 PUFAs
on somatic and mental health is due to their mitigating effects on
dysregulations of three major stress systems: the immune-inflammatory
system, the hypothalamic-pituitary-adrenal-axis (HPA-axis) and the
autonomic nervous system (ANS). These stress systems might in turn
also affect n-3 PUFA levels. Dysregulations in all three systems have
been implicated in the etiology of many somatic and mental disorders
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(Han et al., 2016; Incollingo Rodriguez et al., 2015; Pant et al., 2014;
Penninx et al., 2013). Meta-analyses have shown that levels of in-
flammatory markers such as C-reactive protein (CRP), interleukin (IL)-6
and tumor necrosis factor alpha (TNF-α) are increased in cardiovascular
diseases (Gupta et al., 2017), obesity (Lasselin et al., 2014), rheumatoid
arthritis (Shrivastava et al., 2015) and depression (Kiecolt-Glaser et al.,
2015). Hyperactivity of the HPA-axis have been found in obesity
(Incollingo Rodriguez et al., 2015) and higher cortisol levels at awa-
kening have been observed in depressed patients (Vreeburg et al.,
2009). ANS dysregulation, often indicated by increased heart rate (HR)
and decreased Respiratory Sinus Arrhythmia (RSA) and Pre-Ejection
Period (PEP) reflecting higher sympathetic and lower parasympathetic
tone, has been associated with unfavourable metabolic health (Licht
et al., 2010).
In addition to associations with mental and somatic diseases, the
abovementioned biological stress systems have also been independently
linked with n-3 PUFA levels. For example, in several studies high CRP,
IL-6, and TNF-α plasma levels and chronic inflammatory diseases have
been associated with low n-3 PUFAs plasma levels or intake (Ferrucci
et al., 2006; Yates et al., 2014). Reviews on intervention studies have
shown that n-3 PUFAs are effective in reducing inflammation in certain
inflammatory diseases, such as rheumatoid arthritis (Yates et al., 2014),
however there is no compelling evidence for other somatic diseases
such as myocardial infarction (Hoogeveen et al., 2014). Regarding
mental diseases, n-3 PUFA supplementation has shown to benefit de-
pressed patients in some, but not all trials (Appleton et al., 2015).
With regard to the HPA-axis, were the first to report that elevated
corticotrophin releasing hormone levels, which indirectly stimulates
the synthesis of cortisol, were associated with low n-3 PUFA levels in
humans (Hibbeln et al., 2004). N-3 PUFA deficiency has shown to in-
duce HPA-axis hyperactivity in mice (Larrieu et al., 2014). Further re-
search on the association between HPA-axis and n-3 PUFAs has mainly
been focused on depressed patients. High evening salivary cortisol le-
vels were significantly associated with low DHA plasma levels in de-
pressed patients (Mocking et al., 2013). A decrease in cortisol after n-3
PUFA supplementation has been consistently observed (Hellhammer
et al., 2012). A recent review suggests that the increased ratio of omega-
6 (n-6) PUFA (generally seen as pro-inflammatory) to n-3 PUFAs might
contribute to hyperactivity of the HPA-axis in depression through low-
grade inflammation by means of pro-inflammatory eicosanoids and
cytokines (Husted and Bouzinova, 2016). In turn, cortisol influences the
mobilization (Brenner et al., 2001; Conner et al., 1996; Macfarlane
et al., 2008), lipolysis (Brenner et al., 2001), oxidation (Flerov et al.,
2003; Hibbeln and Salem, 1995) and synthesis (Brenner et al., 2001;
Hibbeln and Salem, 1995) of fatty acids.
Regarding the ANS, only one study examined HR in relation to n-3
PUFA plasma levels and found an inverse association (Eide et al., 2016).
A recent review described a positive association between HR variability
and n-3 PUFA levels in nerve and heart tissue (Christensen, 2011). N-3
PUFA supplements have been able to reduce HR (Skulas-Ray et al.,
2012), increase HR variability (Christensen, 2011) and increase PEP
(Skulas-Ray et al., 2012). Both negative (Brouwer et al., 2006) and
positive (Kromhout et al., 2011) effects of fish/n-3 PUFA supple-
mentation on ventricular arrhythmias have been found, a disease of
which the occurrence can be characterized by HR variability (Farrell
et al., 1991).
It can be concluded that the strongest evidence for an association of
the biological stress systems with n-3 PUFA and DHA is found for the
markers of inflammation, followed by evening cortisol and HR, while
little evidence is found for an association with cortisol at awakening,
RSA and PEP. Most of the studies discussed had small sample sizes and
focused on patients with one specific somatic or mental disorder (for
example depression). Additionally, some used n-3 PUFA intake instead
of plasma levels (which might be more prone to inaccuracy and recall
bias, especially in patients with mood disorders) or studied an asso-
ciated disease (ventricular arrhythmia instead of HR variability). Most
studies only examined a limited number of markers of one stress system
and did not focus on the three biological stress systems together.
Although the interplay between the biological stress systems is well-
known (Straub et al., 2005), the extent to which the cumulative dys-
regulations of these stress systems are associated with low n-3 PUFA
levels is still uncertain.
Therefore, the present large-scaled study aims to establish the as-
sociation of various indicators of inflammation (CRP, IL-6 and TNF-α),
the HPA-axis (awakening and evening cortisol) and the ANS (HR, RSA
and PEP) with n-3 PUFAs and DHA. We hypothesize that high in-
flammation markers, high HPA-axis activity, high sympathetic control
(reflected in high HR and lower PEP) and low parasympathetic control
(reflected in lower RSA) will be associated with low n-3 PUFA and DHA
plasma levels. This study also aims to establish whether there is evi-
dence of an exposure-response relationship between cumulative in-
dicators of biological stress dysregulations and n-3 PUFA and DHA le-
vels, both within and across all three systems.
2. Method and materials
2.1. Study sample
Participants were selected from the Netherlands Study of Depression
and Anxiety (NESDA), a longitudinal observational cohort study
(n= 2981) (Penninx et al., 2008). Between 2004 and 2007 in total
2981 participants aged between 18 and 65 years were recruited from
the Dutch general population (19%), primary health care (54%) and
specialized mental health care (27%). The research protocol was ap-
proved by ethics committees of participating universities. Participants
provided written informed consent and blood samples (after instruc-
tions for overnight fast) and underwent a psychiatric interview. In total
69 participants (2.3%) were excluded due to in-complete blood sam-
ples, 162 participants (5.6%) due to corticosteroids use and 26 parti-
cipants (0.9%) as they were pregnant and/or breastfeeding. The re-
maining participants (n=2724) all had an available measurement on
n-3 PUFA levels and at least one stress system marker. Further exclu-
sions were made for analyses of specific stress markers due to subjects
with missing data, with 8 (0.3%), 9 (0.3%) and 24 (0.9%) missing data
points for CRP, IL-6 and TNF-α, respectively, 931 (34.2%), 931 (34.2%)
and 772 (28.3%) missing data points for AUCg, AUCi and evening
cortisol, respectively, and 117 (4.2%), 115 (4.2%) and 130 (4.8%)
missing data points for HR, RSA and PEP, respectively.
2.2. N-3 PUFAs
A detailed description of the PUFA assessment can be found in a
previous publication (Thesing et al., 2017). In short, fasting blood
samples were collected in EDTA plasma tubes and stored at −80 °C.
The iron chelator EDTA helps to inhibit iron-catalysed oxidation of
PUFA’s. N-3 PUFA and DHA have shown to be relatively stable when
stored at −75 °C (Metherel et al., 2013). Blood samples were shipped in
2 batches for analysis (April and December 2014, further referred to as
metabolic assessment wave 1 and 2, respectively). Among other meta-
bolites, n-3 PUFA levels (including DHA) were quantified at 22 °C using
a commercially available high-throughput proton Nuclear Magnetic
Resonance (NMR) metabolomics platform (Nightingale Health Ltd.,
Helsinki, Finland) (Soininen et al., 2015). Fatty acids measured with
this platform are esterified fatty acids stemming from the lipoprotein
particles, representing fatty acids in the plasma that are bound within
cholesteryl esters, triglycerides and phospholipids inside the lipopro-
teins particles. The DHA signal is quantified separately from a specific
NMR signal unique to this molecule. The resolution of high throughput
NMR does currently not allow sufficient resolution for robust, in-
dependent quantification of EPA due to spectral overlap. As described
in a previous publication (Thesing et al., 2017), we primarily analysed
relative n-3 PUFA measures (as percentage of total fatty acids yielding
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mmol% values), and run secondary analyses using absolute values
(mmol/l). Next to n-3 PUFA levels, levels of other fatty acids (e.g. those
with opposite characteristics such as pro-inflammatory omega-6 (n-6)
PUFAs) are important in the associations with these stress markers.
Therefore, relative measures have found to be biologically more in-
formative, reflecting PUFA levels in relation to overall fatty acids and
better capture for instance the overall effect emerging from the pro-
inflammatory/anti-inflammatory balance. This is supported by a recent
study that found that presentation of fatty acids in either percentages or
concentrations yields different results, particularly for those fatty acids
with a stronger correlation with the total fatty acid level (Mocking
et al., 2012). Finally, because of the pro-inflammatory characteristics of
n-6 PUFA, we created a variable for the n-3:n-6 PUFA ratio, to examine
association with the inflammation markers. Results of these sensitivity
analyses are presented in a supplement.
2.3. Measurement of inflammation, HPA-axis and ANS
A detailed description of the measurement of the markers of in-
flammation, the HPA-axis and ANS can be found in the supplement. For
inflammation, circulating plasma levels of CRP (N=2716), IL-6
(N=2715), and TNF-α (N=2700) were assessed (Vogelzangs et al.,
2012). For HPA-axis, both cortisol at awakening and evening cortisol
were assessed in saliva. The area under the curve with respect to the
ground (AUCg, N=1793) and increase (AUCi, N=1793) were cal-
culated as measures of cortisol awakening response (CAR) with AUCg
reflecting total 1-hour cortisol secretion after awakening, and AUCi the
dynamics of the CAR (Licht et al., 2010). Evening cortisol levels
(N= 1952) are considered to reflect basal cortisol secretion (Licht
et al., 2010). Mixed models analyses were used in a previous study on
the same HPA-axis data by Vreeburg et al. (2009) to create the cortisol
awakening response (CAR) variable when some – but not all – morning
cortisol levels were missing out of 4 saliva samples that were taken over
time (at awakening, 30min, 45min and 60min). The relatively large
number of residual missing data points for HPA-axis markers was
mainly due to participants who did not return saliva samples or col-
lected them outside of a 5min margin around the time protocol
(n=931 for cortisol at awakening and n=772 for evening cortisol).
Respondents on saliva collection did not differ from non-respondents in
sex but were older (44.1 vs 38.2 years, respectively; p < .001), more
educated (12.4 vs 11.6 years of education, respectively; p < .001), and
less likely to be currently depressed (44.2% vs 57.4%, respectively;
p < .001) (Vreeburg et al., 2009). Three ANS measures were derived:
1) heart rate (HR, N=2607), reflecting the combined effect of sym-
pathetic and parasympathetic activity; 2) respiratory sinus arrhythmia
(RSA, N=2609), reflecting parasympathetic activity; 3) pre-ejection
period (PEP, N=2595), reflecting sympathetic activity.
Consistently with a previous paper (Black et al., 2017), we decided a
priori to create cumulative indices for each of the three stress systems
(number of dysregulated markers, range 0–3). Therefore, we dichot-
omized the markers into ‘dysregulated’ (high-risk quartile) versus ‘non-
dysregulated’ (other quartiles), as done previously. Only participants
with complete data on all markers of the respective stress system were
used (98.7%, 54.8% and 94.9% of the total sample of n= 2724 for
inflammation, HPA-axis and ANS, respectively). Additionally, we cal-
culated the sum of the number of stress systems (range 0–3) for which a
subject had one or more markers falling within the high risk quartile.
This cumulative index was only created for subjects who had complete
data on all variables included in the count (42.8% of the sample of
n=2724).
2.4. Covariates and effect modifiers
A distinction was made between potential general confounders (the
same for all biological stress markers) and potential specific con-
founders that differed for the biological stress markers, as done in a
previous papers on the same data (Black et al., 2017). The general
confounders were age (years), gender (male/female), blood sample
collection area (Amsterdam, Leiden, or Groningen), metabolic assess-
ment wave (1 or 2), fasting status at time of blood withdrawal (yes/no),
and n-3 PUFA supplement use (yes/no). Use of n-3 PUFA supplements
was derived from drug container inspection and was considered as this
likely increases PUFA plasma levels.
For analyses on inflammatory markers, we additionally included
systematic anti-inflammatory medication (Vogelzangs et al., 2012). In
analyses with HPA-axis markers, awakening time (00:00–23:59),
working on day of sampling (yes/no), season of sampling (October-
February [less daylight] vs. March-September [more daylight]) were
additionally included in the analysis (Vreeburg et al., 2009). Analyses
with ANS markers, had additional adjustment for use of cardiac medi-
cation including beta-blocking agents and antihypertensive medication
because these were determinants of ANS activity in this study
(Houtveen et al., 2005). Analyses on RSA were additionally adjusted for
respiratory rate. Analyses on PEP were additionally adjusted for mean
arterial pressure ((systolic blood pressure + 2*diastolic blood pres-
sure)/3) to account for potential between-subject differences in after-
load (Houtveen et al., 2005).
As our study over-recruited persons with psychopathology, and as
we previously found lower n-3 PUFA levels among persons with a
current diagnosis of depression (Thesing et al., 2017), we briefly
checked whether depression severity was a confounder or an effect
modifier. Severity of depressive symptoms was based on the 30-item
self-report Inventory of Depressive Symptomatology (IDS-SR30, ran-
ging from 0 to 84) questionnaire, with higher scores indicating higher
severity (Rush et al., 1996). Use of tricyclic antidepressants (TCA’s),
selective serotonin reuptake inhibitors (SSRI’s) and use of other anti-
depressants was based on container inspection (yes/no).
2.5. Statistical analyses
Descriptive statistics were used to describe the study sample. For
subsequent analyses, n-3 PUFA, DHA, CRP, IL-6 and TNF-α were loge
transformed due to skewed distributions. All dependent and in-
dependent variables were standardized to make results for the different
stress markers more comparable. The associations between n-3 PUFA
and DHA and each marker of the biological stress systems were ex-
amined in individual linear regression analyses with n-3 PUFA and DHA
as dependent variables and the markers of the biological stress systems
as independent variables. Markers were used both as continuous vari-
ables and as dichotomous variables (high risk quartile vs. rest). For all
inflammation and HPA-axis markers and heart rate, the 4th quartile
was defined as the high risk quartile. For PEP and RSA, the 1st quartile
was defined as the high risk quartile, reflecting high sympathetic tone
and low parasympathetic tone, respectively. To correct for multiple
testing, the Benjamini-Hochberg False Discovery Rate method was used
based on 36 tests (for 18 markers [both the continuous measures and
high risk quartile measure] and 2 PUFA measures) (Benjamini and
Hochberg, 1995).
Apart from individual stress markers, the accumulation of biological
stressors might lead to even worse health outcomes. We therefore ex-
amined whether a priori made cumulative indices based on the number
of dysregulated markers within one stress system were associated n-3
PUFA and DHA levels. Adjusted analyses of covariance (ANCOVAs)
were performed per stress system to compare the mean n-3 PUFA and
DHA levels (mmol%) between persons with gradually increasing
number of markers in a high risk quartile (ordinal variables with 0, 1, 2
or 3 dysregulated markers). Multivariable linear regression analysis
with the number of dysregulated markers for each stress system as in-
dependent variables and n-3 PUFA or DHA as dependent variables were
performed to test whether stress systems were independently associated
with n-3 PUFA and DHA.
In addition to testing cumulative indicators within a stress system, it
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is also known that biological stress systems interplay and are correlated
(Straub et al., 2005). The accumulation of dysregulations across systems
might lead to even worse health outcomes. Therefore, the mean n-3
PUFA and DHA levels (mmol%) were calculated over each number of
stress systems using adjusted ANCOVAs.
All analyses were repeated with absolute plasma levels (mmol/l) of
n-3 PUFAs and DHA. We also examined potential confounding and ef-
fect modification by depression severity by additionally adding de-
pression severity as a confounder and, in separate analyses, by entering
stress system marker-by-depression severity interaction terms in our
linear regression analyses. Finally, as some antidepressants have been
associated with stress system markers and/or with n-3 PUFA and DHA
previously within this sample (Licht et al., 2010; Thesing et al., 2017;
Vogelzangs et al., 2012) we explored the role of antidepressant medi-
cation. Thus, analyses were repeated excluding antidepressant users. To
check whether there is a potential impact of n-3 PUFA supplement use
on the associations, a second sensitivity analysis was performed in-
cluding only participants who didn’t report n-3 PUFA use. All analyses
were conducted using IBM SPSS statistics software, version 22 (IBM
Corp., Armonk, NY, USA).
Table 1
Characteristics of the study sample.
Mean (SD)/Median
(IQR)/n %
Sociodemographic variables N
Age in years, mean (SD) 2724 41.8 (13.1)
Female, n (%) 2724 1789 (65.7)
Years of education, mean (SD) 2724 12.2 (3.3)
Blood sampling variables
Fasting at time of blood withdrawal, n (%) 2724 2603 (95.6)
Blood sample collection area 2724
Amsterdam, n (%) 1124 (41.3)
Leiden, n (%) 816 (30.0)
Groningen, n (%) 784 (28.8)
Metabolic assessment wave 2724
First, n (%) 1482 (54.4)
Second, n (%) 1242 (45.6)
Specific confounders
Use of systemic anti-inflammatory medication, n
(%)
2724 108 (4.0)
Awakening time (00:00-23:59), mean (SD) 2724 7.46 (1.06)
Working on day of sampling, n (%) 2724 1951 (71.6)
Season of sampling 2724
October–February (less daylight), n (%) 843 (30.9)
March–September (more daylight), n (%) 1881 (69.1)
Use of cardiac medication, n (%) 2724 326 (12.0)
Respiratory rate, mean (SD) 2609 17.6 (1.72)
Mean arterial pressure, median (IQR) 2720 97.8 (17.5)
Psychiatric disorder characteristics
Current depressive disorder, n (%) 2724 779 (28.6)
IDS-SR30, median (IQR) 2717 20.0 (22.0)
Use of antidepressants 2724
No antidepressants, n (%) 2054 (75.4)
TCA, n (%) 72 (2.6)
SSRI, n (%) 455 (16.7)
Other antidepressants, n (%) 143 (5.2)
PUFAs
n-3 PUFA (mmol%), median (IQR) 2724 3.17 (0.94)
DHA (mmol%), median (IQR) 2724 1.12 (0.50)
n-3 PUFA (mmol/l), median (IQR) 2724 0.36 (0.15)
DHA (mmol/l), median (IQR) 2724 0.13 (0.07)
Use of n-3 PUFA supplements, n (%) 2724 108 (4.0)
Inflammation
C-reactive protein (mg/L), median (IQR) 2716 1.19 (2.40)
Interleukin-6 (pg/mL), median (IQR) 2715 0.74 (0.74)
Tumor Necrosis Factor α (pg/mL), median (IQR) 2700 0.80 (0.50)
Hypothalamic Pituitary Adrenal axis
Area under the curve with respect to the ground
(nmol/L/hr), mean (SD)
1793 18.9 (6.97)
Area under the curve with respect to the increase
(nmol/L/hr), mean (SD)
1793 2.12 (6.22)
Evening cortisol (nmol/L), median (IQR) 1952 4.82 (3.24)
Autonomic Nervous System
Heart Rate (bpm), mean (SD) 2607 68.7 (9.73)
Respiratory Sinus Arrhythmia (ms), median
(IQR)
2609 39.5 (32.0)
Pre-injection period (ms), median (IQR) 2594 122.7 (25.3)
Note. Not-normally distributed variables are presented as medians and inter-quartile ranges. SD: Standard deviation. IQR:
Interquartile Range. IDS-SR30: 30-item self-report Inventory of Depressive Symptomatology. DHA: docosahexaenoic acid. n-3:
omega-3. PUFAs: Polyunsaturated fatty acids. Bpm: beats per minute. Ms: milliseconds.
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3. Results
3.1. Patient characteristics
Table 1 shows the demographic characteristics of the total sample
(N=2724). Participants had a mean age of 41.8 (SD=13.1) and 1789
(65.7%) were female. Markers within each stress system were inter-
correlated (all p-values< .01, see Table S1). N-3 PUFA and DHA were
also highly correlated (Spearman r= .85; p < .001). Significant cor-
relations were found between almost all inflammatory markers and
ANS makers (r ranging from -.19 through .20). Furthermore, significant
correlations were found between AUCg and RSA and between evening
cortisol and both RSA and CRP (Table S1).
3.2. Inflammation and PUFAs
After adjustment for confounders and after correction for multiple
testing, high CRP (Beta=-.146, SE= .017, p < .001), high IL-6
(Beta=-.086; SE= .018; p < .001) and high TNF-α (Beta=-.073;
SE= .018; p < .001) were significantly associated with low n-3 PUFA
levels (see Table 2). High IL-6 (Beta=-.052; SE= .018; p= .004) and
high TNF-α (only the high risk quartile: Beta=-.048; SE= .018;
p= .007) were also significantly associated with low DHA. CRP
(Beta=-.058, SE= .018, p= .001), IL-6 (only the high risk quartile,
Beta=-.045, SE= .018, p= .011) and TNF- α (Beta=-.073, SE= .018,
p < .001) were all significantly associated with the n-3:n-6 PUFA ratio
(Table S5).
3.3. HPA-axis and PUFAs
High evening cortisol (only the high risk quartile; Beta=-.077;
SE= .021; p < .001) was associated with low n-3 PUFA levels
(Table 2). High evening cortisol (only the high risk quartile;
Beta=-.054; SE= .021; p= .011) was also significantly associated
with low DHA. For AUCg and AUCi, as expected, negative associations
were found with n-3 PUFA and DHA, however all were non-significant.
3.4. ANS activity and PUFAs
Table 2 shows that high HR (Beta=-.080; SE= .018; p < .001)
was significantly associated with low n-3 PUFA levels, while for DHA a
negative and almost significant association was found. For RSA and
PEP, as expected, positive associations were found with n-3 PUFA and
DHA, however all were non-significant.
3.5. Cumulative index within the biological stress systems and PUFAs
In ANCOVAs exploring the relationship between the cumulative
indices of each of the three systems (0–3 markers) with n-3 PUFA and
DHA, a higher number of inflammation markers in the high risk quartile
was found to be associated with lower n-3 PUFA and DHA levels (p for
linear trend< .001 and< .001, Fig. 1A and D). The group with three
high risk quartile inflammatory markers had significantly lower n-3
PUFA levels compared to the groups with no (Cohen’s d= .60;
p < .001) and one (Cohen’s d= .34; p= .002) high risk quartile in-
flammatory markers. For DHA, the group with three high risk quartile
inflammatory markers had significantly lower DHA levels compared to
the groups with no (Cohen’s d= .36; p= .001) or one (Cohen’s
d= .24; p= .044) high risk quartile inflammatory markers.
A high number of HPA-axis markers in the high risk quartile was
only significantly associated with lower n-3 PUFA levels while not with
lower DHA levels (p for linear trend .006 and .060, Fig. 1B and E). The
group with three high risk quartile HPA-axis markers had significantly
lower n-3 PUFA levels than the group with no markers (Cohen’s
d= .35; p= .012).
A high number of ANS markers in the high risk quartile was only
significantly associated with lower n-3 PUFA levels while not with
lower DHA levels (p for linear trend .024 and .285, Fig. 1C and F). The
groups with three high risk quartile ANS markers had significantly
lower n-3 PUFA levels than the groups with no, one or two markers
(Cohen’s d=0.45; p= .016; Cohen’s d= .60; p= .027; Cohen’s
d= .28; p= .032; respectively).
To confirm whether the association between a stress system and n-3
PUFAs was independent of the other stress systems, the cumulative
indices of the three stress systems were entered together in one model.
The cumulative indices for inflammation and HPA-axis were in-
dependently associated with n-3 PUFA and DHA, but the cumulative
index of ANS was not (Table 3).
Table 2
Linear regression analysis showing the associations between biological stress
measures with n-3 PUFA and DHA (mmol%; dependent variables).
n-3 PUFA (mmol%)a DHA (mmol%)a
Betab SEc p-value Betab SEc p-value
Inflammation
C-reactive protein
Continuousd −.146 .017 < .001* −.031 .018 .089
Highest quartile −.099 .018 < .001* −.010 .018 .57
Interleukin-6
Continuousd −.086 .018 < .001* −.052 .018 .004*
Highest quartile −.110 .018 < .001* −.086 .018 < .001*
Tumor Necrosis Factor α
Continuousd −.073 .018 < .001* −.033 .018 .065
Highest quartile −.090 .018 < .001* −.048 .018 .007*
HPA-axis
Area Under the Curve in
respect to the ground
Continuous −.035 .022 .12 −.017 .022 .44
Highest quartile −.034 .022 .12 −.022 .022 .31
Area Under the Curve in
respect to the increase
Continuous −.016 .022 .47 −.008 .022 .70
Highest quartile −.029 .022 .18 −.017 .022 .42
Evening cortisol
Continuous −.045 .021 .033 −.019 .021 .36
Highest quartile −.077 .021 < .001* −.054 .021 .011*
ANS
Heart Rate
Continuous −.080 .018 < .001* −.032 .019 .099
Highest quartile −.068 .018 < .001* −.036 .018 .054
Respiratory Sinus
Arrhythmia
Continuous .013 .022 .54 .002 .022 .91
Lowest quartile .005 .020 .81 .032 .021 .13
Pre-injection Period
Continuous .000 .018 .99 −.014 .019 .46
Lowest quartile −.031 .019 .099 −.025 .019 .19
Note. Linear regression analyses were conducted with omega-3 Polyunsaturated
Fatty Acids (n-3 PUFA) and docosahexaenoic acid (DHA) in mmol% as de-
pendent variables. Main predictors were individual markers of stress systems
(continuous measure and high risk quartile vs. rest). Adjustment for age,
gender, blood sample collection area, metabolic assessment wave (1 or 2),
fasting (yes/no), n-3 PUFA supplement use (yes/no) and specific confounders:
use of systemic anti-inflammatory medication (yes/no) for inflammation,
awakening time (00:00-23:59), working at day of sampling (yes/no), and
season of sampling (light/dark) for HPA-axis, use of cardiac medication (yes/
no), respiratory rate and mean arterial pressure for ANS activity. HPA-axis:
Hypothalamic Pituitary Adrenal axis. ANS: Autonomic Nervous System.
an-3 PUFA and DHA were transformed according to the natural log.
bStandardized beta. cStandard error of standardized beta. dInflammation mar-
kers were transformed according to the natural log. *Significant after correction
for multiple testing according to the False Discovery Rate of Benjamini-
Hochberg method based on 36 tests for n-3 PUFA and DHA combined.
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3.6. Total cumulative index across dysregulated biological stress systems
and PUFAs
In analyses exploring the relationships between the cumulative
measure of all three systems and n-3 PUFA and DHA, an increasing
number of dysregulated stress systems (with at least one markers within
the high risk quartile) was associated with lower n-3 PUFA levels (p for
linear trend< .001), while for DHA no significant association was
found (p for linear trend .199; Fig. 2). The group with dysregulation in
all three stress systems had significantly lower n-3 PUFA levels than the
groups with dysregulation in no, one or two systems (Cohen’s d= .12;
p < .001; Cohen’s d= .21, p= .001; Cohen’s d= .41, p= .043, re-
spectively).
3.7. Sensitivity analysis
When repeating analyses using absolute levels as opposed to relative
levels of n-3 PUFA and DHA, significant associations were found in the
same direction, for IL-6 and TNF-a with n-3 PUFA and DHA (Table S2).
In contrast to our findings using relative levels, significant associations
were found for low CRP, low HR and high RSA with low DHA and for
high RSA with low absolute levels of n-3 PUFA.
We examined whether found associations were influenced by de-
pression severity, by adding depression severity to the model as an
additional confounder and also by testing stress system marker-by-de-
pression severity interaction terms between the 18 investigated con-
tinuous stress system markers and both n-3 PUFA and DHA. When
adjusting for depression severity, the same significant associations were
found. Subsequently, among the 18 stress system marker-by-depression
severity interaction terms tested, only 1 (for AUCi in the association
with n-3 PUFA) was significant after adjustment for multiple testing.
This suggests that depression is unlikely to have influenced associations
of biological stress markers with n-3 PUFAs and DHA levels. Sensitivity
analyses in subsamples excluding antidepressant users (n=2054) and
users of n-3 PUFA (n=2620) gave similar results (Tables S3 and Table
S4, respectively), suggesting that antidepressant use or n-3 PUFA use do
Fig. 1. Mean levels of plasma n-3 PUFA (A–C) and DHA (mmol%) (D–F) by number of inflammatory markers in high risk quartiles (A and D); number of HPA-axis
markers in high risk quartiles (B and E); number of ANS markers in high risk quartiles (C and F). Fully adjusted ANCOVA’s were performed with log transformed n-3
PUFA and DHA as outcomes. Means and error bars are back-transformed. HPA-axis: hypothalamic pituitary adrenal axis ANS: autonomic nervous system; N: number.
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not influence associations between biological stress markers and n-3
PUFA and DHA.
4. Discussion
The present large-scaled study examined associations of multiple
markers of three major biological stress systems (inflammation, HPA-
axis, and ANS) with n-3 PUFA plasma levels. Overall, it can be con-
cluded that exposure-response relationships were found between on the
one hand having a higher number of markers indicative of inflamma-
tion and having a higher number of markers indicative of a hyperactive
HPA-axis and on the other hand low n-3 PUFA plasma levels. For the
number of dysregulated ANS markers, relationships with n-3 PUFAs
were found only with the highest risk group. Additionally, an exposure-
response relationship was found between having a higher number of
dysregulated stress systems and low n-3 PUFA plasma levels. For DHA,
results were overall in line with those for n-3 PUFA, although with
slightly smaller effect sizes.
Findings were consistent across individual inflammation markers,
with higher levels significantly associated with low n-3 PUFA plasma
levels, which is in line with earlier research (Ferrucci et al., 2006).
Additionally, having multiple dysregulated inflammation markers was
associated with lower levels of n-3 PUFA. While CRP, IL-6 and TNF-α
are mainly seen as pro-inflammatory, n-3 PUFAs are seen as anti-in-
flammatory (Li et al., 2014). One of the mechanisms that might un-
derlie the lowering effect of n-3 PUFA on CRP, IL-6 and TNF-α involves
both nuclear factor kappa B (NF-кB), peroxisome proliferator agonist
receptor (PPAR) and oxidative stress (Li et al., 2014). N-3 PUFAs is a
natural ligand of PPAR, which inhibits the activation of NF-кB, that
initiates genes encoding for TNF-α and IL-6. In turn, TNF-α leads to
phosphorylation of IкBa, an inhibitor of NF-кB. Because high oxidative
stress can lead to the activation of NF-кB, the anti-oxidative effect of n-3
PUFAs may also help explain its lowering effect on TNF-α, IL-6 and
consequently on CRP production (Li et al., 2014). Furthermore, n-3
PUFAs are well known for inhibiting the production of pro-in-
flammatory cytokines such as IL-6 and TNF-α, via the reduction of the
production of pro-inflammatory eicosanoids such as thromboxanes,
some prostaglandins and leukotrienes (Calder, 2006). Although not yet
investigated, pro-inflammatory cytokines are in turn hypothesized to
affect the metabolic pathway (i.e., the fatty acid desaturase FADS gene
cluster (Park et al., 2016)) of n-3 PUFA or the rate of beta-oxidation of
n-3 PUFA. The negative associations between the inflammatory markers
and the n-3:n-6 PUFA ratio are in line with the significant negative
associations between the inflammatory markers and n-3 PUFA. This is
expected as n-3 PUFA and the n-3:n-6 PUFA ratio are highly correlated
(Spearmans rho= .90, p < .001)
For the HPA-axis, evidence was found for an exposure-response
Fig. 2. Mean (a) n-3 PUFA and (b) DHA (mmol%) by number of stress systems
with ≥1 marker in high quartiles. ANCOVA’s were performed with log trans-
formed n-3 PUFA and DHA (mmol%). Mean values and error bars are back-
transformed. Analyses were adjusted as model 2.
Table 3
Linear regression analysis with the three stress systems independently and together as independent variables and n-3 PUFA and DHA levels as the dependent
variables.
Model 1 Model 2
n-3 PUFAa DHAa n-3 PUFAa DHAa
Betab SEc p-value Betab SEc p-value Betab SEc p-value Betab SEc p-value
# of inflammation markers −.152 .018 < .001 −.074 .018 < .001 −.149 .023 < .001 −.077 .023 .001
# of HPA-axis markers −.070 .022 .001 −.044 .022 .043 −.066 .022 .003 −.045 .023 .045
# of ANS markers −.038 .019 .053 −.015 .020 .468 −.027 .023 .245 −.006 .024 .803
Note. HPA: Hypothalamic–pituitary–adrenal axis. ANS: Autonomic Nervous System. N-3 PUFA: omega-3 polyunsaturated fatty acids. DHA: docosahexaenoic acid.
Model 1: separate linear regression analysis per stress system. Model 2: entering the stress systems together in the linear regression analysis. Both models were
adjusted for age, gender, blood sample collection area, metabolic assessment wave (1 or 2), fasting (yes/no), n-3 PUFA supplement use (yes/no) and specific
confounders: use of systemic anti-inflammatory medication (yes/no) for inflammation, awakening time (00:00–23:59), working at day of sampling (yes/no), and
season of sampling (light/dark) for HPA-axis, use of cardiac medication (yes/no), respiratory rate and mean arterial pressure for ANS activity.
an-3 PUFA and DHA were transformed according to the natural log. bStandardized beta. cStandard error of standardized beta.
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relationship between having a high number of markers indicative of a
hyperactive HPA-axis and low n-3 PUFA plasma levels. High evening
cortisol levels were significantly associated with low n-3 PUFA plasma
levels, which is in line with a previous study (Mocking et al., 2013).
Negative but non-significant associations were found between cortisol
at awakening and n-3 PUFA plasma levels. Additionally, having mul-
tiple dysregulated HPA-axis markers was associated with lower levels of
n-3 PUFA. Evening cortisol levels are considered to reflect basal cortisol
secretion: the ability of the HPA-axis to return to lower levels of cortisol
towards the end of the day after the morning peak levels in the cortisol
awakening response (Licht et al., 2010), and may better capture HPA
dysregulations than morning cortisol levels do (Mocking et al., 2013).
Cortisol may affect the mobilization, lipolysis, oxidation and synthesis
of fatty acids (Mocking et al., 2013). In turn, fatty acid alterations affect
the activation and feedback mechanism of the HPA-axis by influencing
glucocorticoid receptor functioning, the transport of cortisol across the
blood-brain barrier and pro- and anti-inflammatory eicosanoids which
influence corticotrophin releasing hormone secretion (Mocking et al.,
2013).
Analyses of the ANS found a non-linear association with n-3 PUFA.
High HR was significantly associated with low n-3 PUFA levels, which
is consistent with a previous study (Eide et al., 2016). HR is a measure
of both parasympathetic and sympathetic control (Licht et al., 2010).
Studies have shown that n-3 PUFAs reduce membrane electrical excit-
ability of the cardiac myocyte by lowering its resting membrane po-
tential and the duration of the refractory period through inhibition of
ion channels, resulting in lower HR (Kang, 2012). The non-significant
association of RSA with n-3 PUFA is not in line with a previous review
which found a positive association between n-3 PUFA levels in nerve
and heart tissue and HR variability, although in these studies HR
variability was expressed by other measures than RSA (Christensen,
2011). This is the first study to investigate associations between PEP
and n-3 PUFA, and therefore our lack of significant association can not
be corroborated.
As expected, associations were largely consistent between absolute
and relative measures of n-3 PUFAs, and between n-3 PUFAs and DHA,
for all stress systems, although some inconsistencies have been noted.
For example, high DHA levels (mmol/l) were associated with high CRP,
which is contrary to some suggestions that n-3 PUFAs are anti-in-
flammatory agents (Smith et al., 2011). This finding may be a chance
finding, yet, this is in line with a recent study that found that relative
and absolute PUFA measures may yield different results, particularly for
those fatty acids with a stronger correlation with the total fatty acid
level (Mocking et al., 2012). The different fatty acids all have a variety
of properties, for example some have anti-inflammatory properties (i.e.
n-3 PUFA and DHA) while other have pro-inflammatory properties (i.e.
n-6 PUFA). Therefore high absolute DHA levels in a person may be
found together with high levels of inflammation markers such as CRP,
because high absolute DHA levels can co-exist next to even higher ab-
solute n-6 PUFA levels, which results in an overall inflammatory state.
This needs to be examined further.
Overall, our findings indicate that – within a stress system – both the
dysregulation of individual markers as the accumulation of dysregu-
lated markers within one stress system is related to lower n-3 PUFAs.
For the number of inflammation and HPA-axis markers, these associa-
tions with n-3 PUFA persisted while adjusting for each other and the
number of dysregulated ANS markers. Additionally, the small but sig-
nificant intercorrelations between the stress systems indicate that the
stress systems do not reflect similar constructs. So, with respect to the
accumulation of dysregulations across stress systems, having more than
one stress system with at least one dysregulated marker was associated
with lower n-3 PUFA levels. Hence, both the dysregulation of individual
stress systems and the accumulation of dysregulated stress systems
seem important. This points to an interplay between biological stress-
systems which is independent from their individual effects, as found by
Straub et al. (2005).
The complex relationship between fatty acids and biological stress
most likely resembles a vicious circle. Low n-3 PUFA levels may have
subtle effects on diverse pathways leading to a pro-inflammatory state
and a chronically heightened stress response. The physiological re-
sponses to biological stress might in turn be a lowering of circulating n-
3 PUFAs, directly, or indirectly via a lowering of n-3 PUFA intake. This
weakens the idea of low n-3 PUFA plasma levels as merely a marker of
overall bad health (innocent bystander) or the conviction that they tag
potentially pathological stress processes (even if they are not yet overtly
clinical). In addition, part of the alterations in fatty acids and biological
stress may be adaptive, i.e. alterations instead of dysregulations (Assies
et al., 2014). Meta-analyses for most diseases in which inflammation,
the HPA-axis or the ANS have a role do not support the use of n-3 PUFA
supplementation in their prevention and/or treatment. Nevertheless,
the results from this study may point to new pathways that could be
modified in order to improve health. Take for example depression. In-
teresting is the finding of Rapaport et al. (2016) in patients with MDD,
showing that it is not necessarily low n-3 PUFA baseline levels that
predict response to supplementation (i.e. correction of an n-3 PUFA
deficit), but baseline inflammatory markers that predict response to
supplementation. Most depression reduction response was seen in EPA
supplemented patients with high inflammatory markers (i.e. the anti-
inflammatory effects of EPA correcting an inflammatory state in the
depressed patients) compared to EPA supplementation in depressed
patients with low inflammatory markers. This fits with our findings as
relationships with total n-3 PUFA levels (including EPA next to DHA)
were stronger than with DHA levels.
Besides DHA, no other constituent of n-3 PUFA was measured, in-
cluding EPA. We measured N-3 PUFA in plasma, and N-3 PUFA levels in
serum, plasma, or erythrocyte membrane phospholipids can vary sub-
stantially based on an individual’s meals in the past weeks or months
and therefore reflect medium-term dietary intake, while fatty acid le-
vels in adipose tissue reflect long-term intake (Thiebaut et al., 2009). In
the present study, participants with a diagnosis of depressive/anxiety
disorder were overrepresented, which could influence the general-
izability of the results to the general population. However, there was no
effect modification or confounding by depression severity so depression
is unlikely to have influenced associations of biological stress markers
with n-3 PUFAs and DHA levels. Results of analyses with HPA-axis data
and the resulting cumulative measures had missing data points due to
non-response. This could potentially bias the observed association if the
missings were selective. Correction for multiple testing has been ap-
plied based the total number of tests in this paper. However, we have
published on PUFAs before using the same dataset and one could sug-
gest to take the number of tests in these papers also into account in the
overall type 1 error rate. Strengths of our study are the inclusion of
multiple markers of biological stress system dysregulations for which
the individual and joint associations with n-3 PUFA were examined,
and the large range of covariates that were taken into account.
5. Conclusions
In summary, it can be concluded that greater dysregulation of (the
markers of) the three biological stress systems is associated with low n-
3 PUFA and, to a lesser extent, with low DHA plasma levels. This im-
plies that n-3 PUFAs are associated with an interplay of these stress
systems, on top of the individual stress systems and their markers. This
relationship is most likely bidirectional. Both low N-3 PUFA levels and
dysregulation of the three stress systems have been associated with
many somatic and mental disorders (Penninx et al., 2013). Intervention
studies with n-3 PUFA supplementation can provide insight whether n-
3 PUFAs are able to reduce biological stress. If low n-3 PUFA levels are
the cause of dysregulated stress systems, then n-3 PUFA supplementa-
tion may be useful in the treatment of many somatic and mental dis-
orders via their mitigating effect on the three major biological stress
systems.
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